slno,preds
0,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Characteristics**:
   - There are two distinct adenocarcinomas: 
     - A 1 cm solid predominant adenocarcinoma in the lingula.
     - A 3.5 cm micropapillary predominant adenocarcinoma in the left lower lobe.
   - Both tumors have free margins, indicating that the surgical resection was complete with no residual tumor at the margins.

2. **Lymph Node Involvement**:
   - There is no lymph node metastasis, which is a favorable prognostic factor as it suggests the cancer has not spread to the lymphatic system.

3. **Molecular Findings**:
   - A positive KRAS mutation is present, which is generally associated with a poorer prognosis and potential resistance to certain therapies.
   - No EGFR mutations were detected, which limits the use of targeted therapies that are effective in EGFR-mutated cancers.

4. **Additional Findings**:
   - Emphysema is noted, which may affect overall lung function but is not directly related to cancer prognosis.
   - The tumors are morphologically distinct, suggesting they may be separate primary cancers rather than metastatic spread from one primary site.

5. **Prognostic Considerations**:
   - The presence of two separate primary tumors can complicate treatment and prognosis.
   - The absence of lymph node metastasis and clear surgical margins are positive factors.
   - The KRAS mutation is a negative prognostic factor.

Considering these factors, the absence of lymph node involvement and clear margins are strong positive indicators for survival. However, the presence of a KRAS mutation and two distinct primary tumors complicates the prognosis. Despite the poor prognosis associated with KRAS mutations, the overall scenario with no lymph node involvement and complete resection suggests a reasonable chance of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
1,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Characteristics**: The tumor is a moderately differentiated adenocarcinoma, which generally indicates a better prognosis compared to poorly differentiated tumors.

2. **Tumor Size and Invasion**: The tumor measures 2.0 x 2.0 x 1.6 cm, which is relatively small. There is focal pleural invasion, but no lymphovascular space invasion is noted. Focal pleural invasion can be concerning, but the absence of lymphovascular invasion is a positive factor.

3. **Lymph Node Involvement**: Multiple lymph nodes were biopsied and all were negative for neoplasm. This indicates no lymph node metastasis, which is a favorable prognostic factor.

4. **Staging**: The tumor is staged as T2N0. T2 indicates a tumor size greater than 3 cm but less than 5 cm or involvement of the main bronchus or visceral pleura. N0 indicates no regional lymph node metastasis. This staging suggests localized disease without lymph node involvement, which is associated with a better prognosis.

Considering these factors, the absence of lymph node involvement, the moderate differentiation of the tumor, and the lack of lymphovascular invasion all suggest a relatively favorable prognosis. Therefore, it is reasonable to conclude that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
2,"The pathology report provides the following key details:

1. **Tumor Characteristics**: The adenocarcinoma is well-differentiated and minimally invasive, with a lepidic pattern. The tumor size is 2.8 cm.

2. **Surgical Margins**: The surgical margins are negative, indicating that the tumor was completely resected.

3. **Invasion**: There is no evidence of lymphovascular invasion or visceral pleura invasion.

4. **Lymph Node Status**: Lymph node examinations from various sites showed no malignancy, indicating no lymph node metastasis.

5. **Staging**: The cancer is staged as pT1b, pN1. The pT1b stage indicates a small tumor size (greater than 2 cm but not more than 3 cm), and pN1 indicates that there is some involvement of regional lymph nodes.

Given these details, the prognosis appears favorable due to the following reasons:

- The tumor is well-differentiated and minimally invasive, which generally suggests a better prognosis.
- Negative surgical margins and no lymphovascular or visceral pleura invasion further support a positive outcome.
- Although there is pN1 staging, indicating some lymph node involvement, the absence of malignancy in sampled nodes suggests limited spread.

Considering these factors, the likelihood of survival beyond 2.48 years is high.

Answer - {""Survival"": ""True""}"
3,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Differentiation**: The adenocarcinoma is described as moderately-poorly differentiated. Poor differentiation generally indicates a more aggressive tumor with a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The tumor measures 2.5 x 2.0 cm. While the size is relatively small, other factors such as lymph node involvement and invasion are more critical in determining prognosis.

3. **Lymph Node Involvement**: Out of twelve examined lymph nodes, ten are involved with metastatic carcinoma, including the subcarinal lymph node. Extensive lymph node involvement is a significant negative prognostic factor, indicating advanced disease and a higher likelihood of systemic spread.

4. **Surgical Margins**: The surgical margins are negative for tumor, which is a positive finding, suggesting that the tumor was completely resected.

5. **Lymphovascular Invasion**: There is extensive lymphovascular invasion noted within the lung tissue. This is another negative prognostic factor, as it suggests that the cancer has the potential to spread through the lymphatic and vascular systems.

Considering these factors, the extensive lymph node involvement and lymphovascular invasion are particularly concerning and suggest a high risk of recurrence and metastasis. Despite the negative surgical margins, the overall prognosis is poor due to the aggressive nature of the disease and the extent of lymph node involvement.

Based on this analysis, the likelihood of survival after 2.48 years is low.

Answer - {""Survival"": ""False""}"
4,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The patient has an invasive poorly differentiated adenocarcinoma in the left upper lobe of the lung, measuring 2.7 cm. Poor differentiation generally indicates a more aggressive tumor, which can negatively impact prognosis.

2. **Visceral Pleura Invasion**: The tumor invades the visceral pleura. Pleural invasion is associated with a higher stage and can indicate a more advanced disease, potentially affecting survival negatively.

3. **Intratumoral Large Vessel Invasion**: The presence of large vessel invasion is a significant adverse prognostic factor, as it suggests a higher likelihood of metastasis and recurrence.

4. **Lymph Node and Distant Metastasis**: The level 5 lymph node resection revealed anthracotic lymph nodes negative for metastatic carcinoma, and no distant metastasis was identified. The absence of lymph node involvement and distant metastasis is a positive factor for survival.

5. **Tumor Staging**: The tumor is staged as pT2a, which indicates a localized tumor without lymph node involvement. This staging suggests that the disease is not advanced in terms of spread.

6. **Parenchymal Margin**: The tumor has a parenchymal margin of 8 mm, which is a clear margin and generally a favorable factor, as it indicates that the tumor was completely resected.

Considering these factors, the presence of poorly differentiated histology and large vessel invasion are significant negative prognostic indicators. However, the absence of lymph node involvement and distant metastasis, along with a clear surgical margin, are positive factors. The balance of these factors suggests a guarded prognosis, but the absence of metastasis and clear margins may allow for a reasonable chance of survival beyond 2.48 years, depending on additional treatments and patient factors.

Answer - {""Survival"": ""True""}"
5,"The pathology report provides the following key details:

1. **Diagnosis**: Invasive mucinous adenocarcinoma in the right upper lobe of the lung.
2. **Tumor Size**: 2.5 cm.
3. **Margins**: Clear margins with no residual tumor after completion lobectomy.
4. **Lymph Nodes**: All examined lymph nodes (levels 4, 7, and 10) are negative for carcinoma, indicating no regional lymph node metastasis.
5. **Molecular Studies**: Positive KRAS mutation (p.G12C) and no EGFR mutations detected.

**Analysis**:

- **Tumor Size and Margins**: The tumor is relatively small (2.5 cm) and has clear surgical margins, which is a favorable factor for prognosis.
- **Lymph Node Status**: The absence of regional lymph node metastasis is a positive prognostic indicator, as it suggests localized disease without spread to lymph nodes.
- **Molecular Studies**: The presence of a KRAS mutation (p.G12C) is associated with a poorer prognosis and potential resistance to certain therapies, which could negatively impact survival. However, the absence of EGFR mutations is neutral in this context.

**Conclusion**:

Despite the presence of a KRAS mutation, the overall pathology report suggests a localized disease with clear margins and no lymph node involvement, which are strong positive prognostic factors. The tumor's small size and the absence of metastasis are also favorable. Therefore, the likelihood of survival beyond 2.48 years is reasonable.

Answer - {""Survival"": ""True""}"
6,"The pathology report provides the following key information:

1. **Invasive Grade 3 Adenocarcinoma**: This indicates a high-grade tumor, which generally suggests a more aggressive cancer with a poorer prognosis.

2. **Tumor Size and Margins**: The tumor measures 5 x 4 x 3 cm, and the bronchial margins are negative, indicating that the surgical resection was complete with no residual tumor at the margins.

3. **Lymph Node Involvement**: One of six intrapulmonary peribronchial lymph nodes tested positive for metastatic adenocarcinoma. This indicates regional lymph node involvement, which is a negative prognostic factor.

4. **Necrotizing Granuloma and Granulomatous Lymphadenitis**: The presence of necrotizing granuloma in the right upper lobe and necrotizing granulomatous lymphadenitis in multiple mediastinal lymph nodes, which are negative for tumor, suggests an inflammatory or infectious process rather than cancer spread.

5. **Special Stains for Microorganisms**: These were negative on the subcarinal lymph nodes, ruling out certain infections.

Considering these factors:

- The presence of metastatic adenocarcinoma in one lymph node indicates that the cancer has started to spread beyond the primary site, which is a significant factor in determining prognosis.
- The high-grade nature of the tumor (Grade 3) also suggests a more aggressive disease course.
- However, the negative bronchial margins and the absence of tumor in the mediastinal lymph nodes are positive factors.

Overall, the presence of lymph node metastasis and the high-grade nature of the tumor suggest a poorer prognosis, making survival beyond 2.48 years less likely.

Answer - {""Survival"": ""False""}"
7,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Diagnosis and Differentiation**: The patient has a moderately differentiated adenocarcinoma. Moderate differentiation generally indicates a better prognosis compared to poorly differentiated tumors.

2. **Tumor Size and Location**: The tumor is 2.3 cm in size, located in the right lung lower lobe. A tumor size of 2.3 cm falls within the T1b category, which is considered a relatively small tumor.

3. **Margins and Invasion**: The carcinoma extends to within 1 mm of the staple line but does not invade the visceral pleura. The absence of visceral pleura invasion is a positive factor, as pleural invasion can indicate a more aggressive disease.

4. **Lymph Node Involvement**: No metastatic carcinoma was identified in the examined lymph nodes, indicating N0 status. The absence of lymph node involvement is a favorable prognostic factor.

5. **Staging**: The final staging is pT1b N0, which suggests localized disease without lymph node involvement. This stage is generally associated with a good prognosis and higher survival rates.

6. **Recommendations**: Clinical correlation and follow-up are recommended, which is standard practice to monitor for any recurrence or progression.

Considering these factors, the prognosis for this patient appears favorable, with a high likelihood of survival beyond 2.48 years. The tumor is small, localized, and without lymph node involvement, all of which are positive indicators.

Answer - {""Survival"": ""True""}"
8,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Differentiation**: The adenocarcinoma is moderately differentiated, which generally indicates an intermediate prognosis compared to well-differentiated (better prognosis) and poorly differentiated (worse prognosis) tumors.

2. **Lymph Node Involvement**: There is metastatic involvement in one of four hilar lymph nodes. Lymph node involvement is a negative prognostic factor, as it suggests some spread of the cancer beyond the primary tumor site.

3. **Surgical Margins**: The surgical margins, including the bronchial resection margin, are negative for carcinoma. This is a positive factor, as it indicates that the tumor was likely completely resected.

4. **Pleural and Angiolymphatic Invasion**: There is no evidence of pleural involvement or angiolymphatic invasion. The absence of these factors is favorable, as their presence would suggest a higher risk of further spread.

5. **Additional Findings**: The presence of hyalinized granulomata in other lymph nodes is not directly related to the cancer prognosis but indicates some other benign process.

Considering these factors, the presence of lymph node metastasis is a significant concern, but the absence of pleural and angiolymphatic invasion, along with clear surgical margins, are positive indicators. The moderately differentiated nature of the tumor also suggests an intermediate prognosis. Overall, while the lymph node involvement is a negative factor, the other positive factors suggest a reasonable chance of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
9,"1. **Tumor Characteristics**: The tumor is described as an invasive well-differentiated adenocarcinoma with a predominant bronchiolo-alveolar carcinoma component. Well-differentiated tumors generally have a better prognosis compared to poorly differentiated ones.

2. **Size and Location**: The tumor measures approximately 50 x 60 x 45 mm and is located in the left lower lobe. While the size is relatively large, the absence of other aggressive features is more critical for prognosis.

3. **Invasion and Metastasis**: There is no evidence of vascular or perineural invasion, and no metastases to hilar lymph nodes are noted. The absence of lymph node involvement and lack of vascular invasion are positive prognostic factors.

4. **Pleural Involvement**: Although the tumor closely abuts the pleural surface, confirmatory stains suggest that the pleura is likely not involved. This is important as pleural involvement can worsen the prognosis.

5. **Additional Findings**: A separate specimen from the back shows features consistent with a lipoma, which is benign and not related to the malignancy.

6. **Overall Assessment**: The combination of a well-differentiated tumor, absence of lymph node metastasis, no vascular or perineural invasion, and likely no pleural involvement suggests a favorable prognosis.

Based on these considerations, the likelihood of survival after 2.48 years is high.

Answer - {""Survival"": ""True""}"
10,"The pathology report provides the following key details:

1. **Tumor Size and Differentiation**: The tumor is a poorly differentiated adenocarcinoma measuring 3 x 3 x 3 cm. Poor differentiation generally indicates a more aggressive tumor with a worse prognosis compared to well-differentiated tumors.

2. **Visceral Pleura Invasion**: The tumor has invaded the visceral pleura. Pleural invasion is associated with a higher stage of cancer and can negatively impact prognosis.

3. **Lymph Node Metastasis**: There is metastasis in 1 out of 1 examined lymph node. The presence of lymph node metastasis is a significant factor that worsens the prognosis, as it indicates that the cancer has started to spread beyond the primary site.

4. **Immunohistochemical Staining**: The tumor is positive for CD15, CK7, TTF1, and CEA, and negative for CK20 and CDX2. These markers are consistent with lung adenocarcinoma, but they do not directly impact the prognosis in terms of survival prediction.

Considering these factors, the presence of poorly differentiated adenocarcinoma, pleural invasion, and lymph node metastasis suggests a more advanced stage of cancer with a poorer prognosis. These factors collectively indicate a lower likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""False""}"
11,"The pathology report provides the following key details:

1. **Tumor Size and Location**: The tumor is located in the left lower lobe of the lung and measures 4.0 x 3.5 x 2.0 cm.

2. **Diagnosis**: The tumor is diagnosed as adenocarcinoma of mixed subtype, predominantly papillary.

3. **Visceral Pleura Infiltration**: There is infiltration of the visceral pleura, which can indicate a more aggressive tumor behavior.

4. **Tumor Classification**: The tumor is classified as pT2, which generally indicates a tumor size greater than 3 cm but less than or equal to 5 cm, or a tumor that invades the visceral pleura.

5. **Lymph Node Involvement**: There is no regional lymph node involvement (0/20), which is a favorable prognostic factor.

6. **Distant Metastasis Status**: The distant metastasis status is unknown (pMx), which means it is not clear if the cancer has spread to distant sites.

7. **Tumor Grade**: The tumor grade is G2, indicating moderate differentiation. This suggests an intermediate level of aggressiveness.

Considering these factors:

- The absence of lymph node involvement is a positive prognostic factor.
- The moderate differentiation (G2) and visceral pleura infiltration suggest an intermediate prognosis.
- The unknown status of distant metastasis (pMx) introduces some uncertainty, but without evidence of distant metastasis, the prognosis may still be relatively favorable.

Based on these considerations, the likelihood of survival after 2.48 years is reasonably optimistic, assuming no distant metastasis is present.

Answer - {""Survival"": ""True""}"
12,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The adenocarcinoma is moderately differentiated and measures 2.7 cm. Moderately differentiated tumors generally have an intermediate prognosis compared to well-differentiated (better prognosis) and poorly differentiated (worse prognosis) tumors.

2. **Invasion and Margins**: There is no angiolymphatic invasion or pleural involvement, and the bronchial margin is negative. These are favorable factors, as they suggest the tumor has not spread extensively within the lung or to surrounding structures.

3. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in 1 out of 4 peribronchial lymph nodes. However, no metastatic carcinoma was identified in the R4 and station 11 lymph nodes. The presence of metastasis in one lymph node indicates some regional spread, which can affect prognosis, but the absence of metastasis in other examined nodes is a positive sign.

4. **Surgical Margins and Additional Lesions**: The surgical margins are negative for tumor involvement, and no additional lesions were noted in the surrounding lung tissue. This suggests that the tumor was likely completely resected, which is a positive prognostic factor.

Considering these factors, the presence of metastasis in one lymph node does indicate some spread, but the overall findings, including the lack of extensive invasion, negative surgical margins, and absence of additional lesions, suggest a relatively favorable prognosis. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
13,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Size and Differentiation**: The tumor is relatively small at 1.2 cm, which is generally favorable. However, it is classified as moderately to poorly differentiated, which can indicate a more aggressive tumor behavior.

2. **Surgical Margins**: All surgical margins are free of tumor, which is a positive indicator as it suggests that the tumor has been completely resected.

3. **Visceral Pleura Invasion**: There is focal invasion into the visceral pleura. While this is a concern, it is not necessarily a definitive indicator of poor prognosis, especially if the invasion is minimal.

4. **Lymphatic Invasion**: There is a focus suggestive of lymphatic invasion, which can be a negative prognostic factor as it may indicate potential for metastasis.

5. **Lymph Node Involvement**: No lymph node involvement was detected among the seven examined, which is a positive factor as lymph node metastasis is a significant predictor of poor prognosis.

6. **Further Mutation Analysis**: The recommendation for further mutation analysis for EGFR and KRAS suggests that targeted therapy options may be available, which could improve prognosis if actionable mutations are found.

Considering these factors, the small tumor size, absence of lymph node involvement, and clear surgical margins are positive indicators. The presence of focal pleural and possible lymphatic invasion are concerns, but without lymph node involvement, the prognosis may still be relatively favorable. The potential for targeted therapy based on mutation analysis could also improve outcomes.

Based on this analysis, the likelihood of survival after 2.48 years is more likely to be positive.

Answer - {""Survival"": ""True""}"
14,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Characteristics**: The adenocarcinoma is acinar type, grade III, which indicates a poorly differentiated tumor. Poor differentiation is generally associated with a more aggressive cancer and a worse prognosis.

2. **Tumor Size and Invasion**: The tumor measures 4 cm and invades the visceral pleura. Pleural invasion can be a negative prognostic factor as it suggests more advanced local disease.

3. **Margins**: The bronchial and vascular margins are negative, which is a positive factor as it indicates that the tumor has been completely resected in those areas.

4. **Lymph Node Involvement**: Metastatic adenocarcinoma is identified in two of four lymph nodes examined. This indicates regional lymph node involvement, which is a significant negative prognostic factor.

5. **Staging**: The cancer is staged as pT2, N2, Mx. The T2 stage indicates a tumor size of more than 3 cm but less than 5 cm, with pleural invasion. N2 indicates metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes, which is associated with a more advanced stage of cancer. Mx means that distant metastasis cannot be assessed, but the presence of N2 already suggests a more advanced disease.

Considering these factors, the presence of lymph node metastasis (N2) and the high-grade nature of the tumor (grade III) are significant negative prognostic indicators. These factors suggest a lower likelihood of survival after 2.48 years.

Answer - {""Survival"": ""False""}"
15,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report indicates an invasive moderately differentiated adenocarcinoma measuring 9.2 cm. The size and differentiation level suggest a significant tumor burden, but not the most aggressive form.

2. **Invasion and Margins**: The tumor has invaded the chest wall, which is a concerning factor as it indicates local advancement. However, the surgical margins are negative for carcinoma, suggesting that the tumor was completely resected, which is a positive prognostic factor.

3. **Lymph Node Involvement**: All 19 examined peribronchial lymph nodes are negative for carcinoma, indicating no regional lymph node metastasis. This is a favorable finding as lymph node involvement often correlates with a worse prognosis.

4. **Pathological Staging**: The tumor is staged as pT3, which indicates a larger tumor size and/or local invasion (such as into the chest wall), but without lymph node involvement (N0) or distant metastasis (M0). This stage suggests a locally advanced disease but not metastatic.

5. **Additional Findings**: Chronic inflammation and emphysematous changes are noted in the non-neoplastic lung tissue, which may affect overall lung function but are not directly related to cancer prognosis.

Considering these factors, the absence of lymph node involvement and negative surgical margins are positive indicators. However, the invasion into the chest wall and the size of the tumor are concerning. Overall, while the prognosis is guarded due to the local advancement (pT3), the lack of lymph node involvement and negative margins suggest a reasonable chance of survival beyond 2.48 years, assuming no distant metastasis develops.

Answer - {""Survival"": ""True""}"
16,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key findings:

1. **Diagnosis**: The patient has lung adenocarcinoma, which is a type of non-small cell lung cancer.

2. **Tumor Characteristics**: The primary tumor is moderately differentiated and measures 6.9 cm. It shows visceral pleural invasion and lymphangitic invasion, which are indicators of aggressive behavior.

3. **Lymph Node Involvement**: Metastatic adenocarcinoma was identified in lymph nodes from the left level 9 and two out of five lymph nodes from the left level 11. This indicates regional lymph node involvement.

4. **No Distant Metastasis**: There is no evidence of distant metastasis, which is a positive factor in terms of prognosis.

5. **Overall Staging**: The presence of regional lymph node involvement and visceral pleural invasion suggests a more advanced stage of lung cancer, likely stage III. This stage is associated with a lower survival rate compared to earlier stages.

Considering these factors, the presence of regional lymph node involvement and visceral pleural invasion, along with the size of the tumor, suggests a poor prognosis. Although there is no distant metastasis, the regional spread and aggressive features of the tumor indicate a high risk of recurrence and progression, which negatively impacts survival.

Therefore, based on the information provided, it is unlikely that the patient will survive after 2.48 years.

Answer - {""Survival"": ""False""}"
17,"The pathology report provided lacks specific diagnostic information about the tumor type, its size, grade, stage, or any other relevant pathological features that would allow for an assessment of the patient's prognosis or survival likelihood. Without this critical information, it is impossible to make an informed determination about the patient's survival after 2.48 years.

Answer - {""Survival"": ""False""}"
18,"To determine if the patient will survive after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Diagnosis and Tumor Characteristics**: The patient has a well-differentiated papillary non-mucinous adenocarcinoma in the right lower lobe, measuring 50 mm. Well-differentiated tumors generally have a better prognosis compared to poorly differentiated ones.

2. **Tumor Extension and Margins**: The tumor extends to the visceral pleura but is tumor-free, indicating no invasion through the pleura. The resection margins are clear (R0), which is a positive prognostic factor as it suggests complete surgical removal of the tumor.

3. **Staging**: The tumor is classified as pT2, pN0, pMX, and stage I B. 
   - **pT2**: Tumor size and/or local extent is significant but not beyond the pleura.
   - **pN0**: No regional lymph node involvement, which is favorable.
   - **pMX**: Distant metastasis cannot be assessed, but no evidence of metastasis is noted.
   - **Stage I B**: Early-stage cancer, generally associated with a better prognosis.

4. **Additional Findings**: Subpleural scarring and pleural adhesions are noted, but these do not indicate malignancy or affect prognosis significantly.

Considering these factors, the patient has a well-differentiated tumor with no lymph node involvement, clear surgical margins, and is at an early stage (I B). These are all positive indicators for survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
19,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes a poorly differentiated adenocarcinoma measuring 4.5 cm. Poor differentiation generally indicates a more aggressive tumor with a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: There is visceral pleural and lymphovascular invasion, and the tumor is present at the pleural surface. These features suggest a more advanced and aggressive disease, as invasion into these areas can facilitate the spread of cancer.

3. **Lymph Node Involvement**: One of the six lymph nodes examined contains metastatic carcinoma with extracapsular extension. Lymph node involvement, especially with extracapsular extension, is a negative prognostic factor as it indicates that the cancer has spread beyond the primary site.

4. **Staging**: The tumor is staged as pT2aN1MX. The T2a stage indicates a tumor size between 3 and 5 cm with certain invasive characteristics. N1 indicates regional lymph node involvement, which is associated with a higher risk of recurrence and metastasis. MX means that distant metastasis cannot be assessed, which leaves uncertainty regarding the spread of the disease.

Considering these factors, the presence of poorly differentiated adenocarcinoma with lymphovascular invasion, pleural involvement, and lymph node metastasis with extracapsular extension suggests a more aggressive cancer with a higher risk of recurrence and metastasis. These characteristics generally correlate with a poorer prognosis and lower survival rates.

Therefore, based on the pathology report, the likelihood of survival after 2.48 years is low.

Answer - {""Survival"": ""False""}"
20,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, we need to consider several factors typically associated with prognosis in lung cancer:

1. **Tumor Differentiation**: The report describes the tumor as ""poorly differentiated,"" which generally indicates a more aggressive cancer with a potentially worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The tumor measures 2.5 x 1.5 x 3 cm. While this size is not extremely large, the lack of information on other critical factors makes it difficult to assess the full extent of the disease.

3. **Lymph Node Involvement**: The report does not specify whether there is lymph node involvement. Lymph node metastasis is a significant factor in determining prognosis, and the absence of this information leaves a gap in assessing the stage of the cancer.

4. **Invasion and Metastasis**: There is no information on whether the tumor has invaded surrounding tissues or if there are distant metastases. These factors are crucial in staging the cancer and predicting survival.

5. **Additional Findings**: The report lacks comments on other nodules, invasion, or additional findings, which are important for a comprehensive assessment.

Given the limited information, particularly the absence of details on lymph node involvement, invasion, and metastasis, it is challenging to make a definitive prediction. However, the poorly differentiated nature of the tumor suggests a more aggressive disease, which could potentially lead to a poorer prognosis.

Based on the available information, and considering the aggressive nature of poorly differentiated tumors, the likelihood of survival after 2.48 years may be lower. Therefore, the most cautious approach would be to assume a less favorable outcome.

Answer - {""Survival"": ""False""}"
21,"The pathology report provides the following key details:

1. **Tumor Characteristics**: The tumor is a moderately-differentiated adenocarcinoma, which generally indicates a better prognosis compared to poorly differentiated tumors.

2. **Size and Location**: The tumor measures 2.5 cm and is located in the left upper lobe of the lung.

3. **Margins**: The surgical margins are negative, meaning the tumor has been completely excised with no cancer cells at the edges of the removed tissue.

4. **Invasion**: There is no evidence of vascular or lymphatic invasion, which is a positive prognostic factor as it suggests the cancer has not spread through blood vessels or lymphatic channels.

5. **Lymph Nodes**: All examined regional lymph nodes (five in total) are negative for malignancy, indicating no regional lymph node metastasis.

6. **Pleural Involvement**: The tumor shows invasion towards the pleural surface but does not directly involve the visceral pleura. This suggests limited pleural involvement, which is less concerning than direct invasion.

Based on these factors, the prognosis appears favorable. The absence of lymph node involvement, vascular invasion, and negative margins are all positive indicators for survival. The moderately-differentiated nature of the tumor also suggests a better outcome compared to more aggressive forms.

Therefore, the likelihood of survival after 2.48 years is high.

Answer - {""Survival"": ""True""}"
22,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Metastatic Carcinoma in Multiple Lymph Nodes**: The presence of metastatic carcinoma in multiple lymph nodes is a significant indicator of advanced disease. Lymph node involvement generally suggests a poorer prognosis due to the spread of cancer beyond the primary site.

2. **Poorly Differentiated Adenocarcinoma**: Poor differentiation in adenocarcinoma is associated with a more aggressive tumor and a worse prognosis compared to well-differentiated tumors.

3. **Tumor Size**: The primary tumor size is 1.7 cm, which is relatively small. However, the size is less critical in this context due to the presence of metastatic disease.

4. **Capsular Penetration and Lymphatic Invasion**: These findings indicate aggressive tumor behavior and further support the likelihood of systemic disease spread.

5. **Negative Surgical Margins**: While negative margins are generally a positive finding, indicating that the tumor was completely resected at the primary site, the presence of metastatic disease in lymph nodes overshadows this benefit.

6. **Exclusion of Breast Carcinoma as Source**: This confirms the primary site as pulmonary, which is relevant for treatment planning but does not directly impact the prognosis in this context.

Given the presence of metastatic carcinoma in multiple lymph nodes, poorly differentiated histology, and evidence of lymphatic invasion, the prognosis is poor. These factors collectively suggest a high likelihood of disease progression and reduced survival probability.

Answer - {""Survival"": ""False""}"
23,"The pathology report indicates the following key findings:

1. **Moderately Differentiated Adenocarcinoma**: The tumor is moderately differentiated, which generally suggests a better prognosis compared to poorly differentiated tumors.

2. **Tumor Size**: The adenocarcinoma measures 2.0 cm, which is relatively small.

3. **Clear Surgical Margins**: The surgical margins are clear, indicating that the tumor has been completely excised with no residual cancerous tissue at the edges of the removed tissue.

4. **No Pleural Involvement**: There is no involvement of the pleura, which is a positive prognostic factor as pleural invasion can indicate a more advanced disease.

5. **Negative Lymph Nodes**: The excised lymph nodes from various levels, including levels IX and XI, are negative for malignancy, indicating no regional lymph node metastasis.

6. **Localized Disease**: The findings suggest a localized lung adenocarcinoma with no evidence of metastasis.

Based on these findings, the patient has a localized, moderately differentiated adenocarcinoma with no lymph node involvement or pleural invasion, and clear surgical margins. These factors collectively suggest a favorable prognosis and a higher likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
24,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Size and Location**: The adenocarcinoma is located in the left upper lobe of the lung, measuring 6.5 x 6.5 x 5.0 cm. This size classifies the tumor as pT2b, indicating a larger tumor but still within a potentially resectable range.

2. **Lymph Node Involvement**: The classification pN1 (6/28) indicates that there is regional lymph node involvement, with 6 out of 28 lymph nodes showing metastasis. Lymph node involvement generally suggests a more advanced disease and can negatively impact prognosis.

3. **Metastasis**: The classification pMx indicates that distant metastasis cannot be assessed. The absence of confirmed distant metastasis is somewhat favorable, but the inability to assess it leaves some uncertainty.

4. **Tumor Grade**: The tumor is graded as G3, which means it is poorly differentiated. Poorly differentiated tumors tend to have a worse prognosis due to their aggressive nature.

5. **Immunohistochemical Analysis**: The tumor cells are positive for CK7 and have a Ki-67 proliferation index of 40%. A high Ki-67 index suggests a high proliferation rate, which is often associated with more aggressive tumors.

Considering these factors:
- The presence of lymph node involvement (pN1) and a high Ki-67 index are concerning for prognosis.
- The tumor is poorly differentiated (G3), which also suggests a more aggressive disease.
- The lack of confirmed distant metastasis is somewhat favorable, but the inability to assess it leaves some uncertainty.

Overall, the combination of lymph node involvement, high proliferation index, and poor differentiation suggests a more aggressive cancer with a potentially poorer prognosis. Therefore, the likelihood of survival after 2.48 years is less favorable.

Answer - {""Survival"": ""False""}"
25,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Metastatic Adenocarcinoma**: The presence of metastatic disease indicates that the cancer has spread beyond the primary site, which generally suggests a more advanced stage and a poorer prognosis.

2. **Lymph Node Involvement**: Eight out of twelve lymph nodes are positive for cancer, and additional lymph nodes are affected. This extensive lymph node involvement is indicative of a significant spread of the disease, which is associated with a lower survival rate.

3. **Tumor Characteristics**: The tumor is described as moderately to poorly differentiated, which typically correlates with a more aggressive cancer and a worse prognosis.

4. **Lymphovascular Invasion**: The presence of lymphovascular invasion suggests that the cancer has the potential to spread further, which negatively impacts survival.

5. **Direct Extension into Intraparenchymal Lymph Nodes**: This finding further supports the aggressive nature of the cancer and its potential for further spread.

6. **Molecular Analysis**: No EGFR mutations were detected, which means that certain targeted therapies may not be effective. The presence of a polymorphism of uncertain clinical significance does not provide clear guidance on prognosis or treatment.

Considering these factors, the extensive lymph node involvement, metastatic nature, and aggressive characteristics of the tumor suggest a poor prognosis. Therefore, the likelihood of survival after 2.48 years is low.

Answer - {""Survival"": ""False""}"
26,"1. **Tumor Characteristics**: The invasive adenocarcinoma is classified as histologic grade 2/4, which indicates a moderately differentiated tumor. The tumor size is 3.5 cm, which is relatively small.

2. **Lymph Node Involvement**: The report mentions that the majority of lymph nodes show no tumor presence, except for hilar node #2, which contains metastatic adenocarcinoma. This indicates some lymph node involvement, classified as pN1.

3. **Visceral Pleura and Vascular Invasion**: There is no invasion of the visceral pleura or large vessels, which is a positive prognostic factor.

4. **Resection Margins**: The resection margins are clear of the tumor, suggesting that the tumor was completely removed during surgery.

5. **TNM Staging**: The TNM stage is pT2a, pN1, pMX. The pT2a indicates a tumor size between 3 and 5 cm without invasion into the visceral pleura or main bronchus. The pN1 indicates regional lymph node involvement. The pMX indicates that distant metastasis cannot be assessed.

6. **Prognosis Consideration**: While the presence of metastatic adenocarcinoma in one lymph node (pN1) is a concern, the absence of visceral pleura and vascular invasion, along with clear resection margins, are favorable factors. The moderately differentiated nature of the tumor (grade 2/4) also suggests a better prognosis compared to poorly differentiated tumors.

Based on these factors, the prognosis is cautiously optimistic, and the patient may survive beyond 2.48 years, although close monitoring and potential adjuvant therapy may be necessary.

Answer - {""Survival"": ""True""}"
27,"The pathology report indicates the following key findings:

1. **Diagnosis**: Adenocarcinoma in the left upper lobe of the lung with components of solid, acinar, and bronchioloalveolar cell carcinoma.
2. **Metastasis**: Evidence of metastatic adenocarcinoma in peribronchial lymph nodes.
3. **Tumor Size and Invasion**: The tumor measures 3.5 x 2.8 x 2.5 cm and invades the visceral pleura.
4. **Vascular and Lymphatic Invasion**: No vascular invasion is noted, but lymphatic invasion is pending.
5. **Additional Findings**: Centrilobular emphysema, pulmonary hemosiderosis, and necrotizing granulomas in the lymph nodes. Some lymph nodes are negative for neoplasm.

**Analysis**:
- The presence of metastatic adenocarcinoma in peribronchial lymph nodes indicates that the cancer has spread beyond the primary tumor site, which is a negative prognostic factor.
- The invasion of the visceral pleura suggests a more advanced local disease, which can also negatively impact prognosis.
- The absence of vascular invasion is a positive factor, but the pending status of lymphatic invasion leaves uncertainty regarding further spread.
- The additional findings (centrilobular emphysema, pulmonary hemosiderosis, and necrotizing granulomas) do not directly impact the prognosis of the adenocarcinoma but indicate other lung pathologies.

Given the metastatic involvement of lymph nodes and pleural invasion, the prognosis is likely poor, and survival beyond 2.48 years is uncertain.

Answer - {""Survival"": ""False""}"
28,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The tumor is a poorly differentiated adenocarcinoma, which generally indicates a more aggressive cancer with a poorer prognosis compared to well-differentiated tumors.

2. **Size and Location**: The tumor measures 58 mm and is located in the right upper lobe of the lung. It has invaded the visceral pleura and the chest wall, which suggests a more advanced local disease.

3. **Margins and Invasion**: The bronchial resection margin is clear, which is a positive factor as it indicates that the tumor was completely resected in that area. However, there is evidence of blood vessel invasion, which is a negative prognostic factor as it suggests potential for hematogenous spread.

4. **Lymphatic and Perineural Invasion**: There is no lymphatic or perineural invasion, which is a positive finding as these types of invasions are associated with worse outcomes.

5. **Lymph Node Metastasis**: No lymph node metastases were found, which is a positive prognostic factor as lymph node involvement typically indicates a higher stage and worse prognosis.

6. **Chest Wall and Rib Involvement**: Although there was initial involvement of the chest wall, further examination revealed no residual malignancy in the chest wall tissues or rib bone, which is a positive finding.

Considering these factors, the presence of blood vessel invasion and the poorly differentiated nature of the tumor are concerning for a poorer prognosis. However, the absence of lymph node metastasis, clear bronchial margins, and no residual malignancy in the chest wall or ribs are positive factors. The overall prognosis is mixed, but given the aggressive nature of the tumor and blood vessel invasion, the likelihood of survival beyond 2.48 years is uncertain and potentially unfavorable.

Answer - {""Survival"": ""False""}"
29,"To determine the likelihood of survival after 2.48 years based on the given pathology report, let's analyze the key details:

1. **Tumor Differentiation**: The tumor is described as poorly differentiated adenocarcinoma. Poor differentiation generally indicates a more aggressive tumor, which can be associated with a worse prognosis.

2. **Tumor Size**: The tumor measures 3.5 x 3 cm. While not extremely large, the size is significant but not necessarily indicative of a poor prognosis on its own.

3. **Venous Invasion**: There is no evidence of venous invasion, which is a positive factor as venous invasion can facilitate metastasis.

4. **Lymph Node Involvement**: Seven hilar lymph nodes were examined, and all showed reactive changes but were negative for metastasis. The absence of lymph node metastasis is a favorable prognostic factor.

5. **Surgical Margins**: The surgical margins are uninvolved, suggesting that the tumor was completely resected, which is another positive factor for prognosis.

Considering these factors, the absence of lymph node metastasis, no venous invasion, and complete resection with uninvolved margins are all positive indicators for survival. Despite the poor differentiation, the overall prognosis appears favorable for survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
30,"1. **Tumor Characteristics**: The primary tumor is a solid predominant adenocarcinoma measuring 3.7 cm. This size is relatively small, which is generally favorable for prognosis.

2. **Stage**: The tumor is classified as Stage IIB. Stage IIB indicates a more advanced local disease but without distant metastasis. This stage can have a variable prognosis depending on other factors.

3. **Lymph Node Involvement**: All 11 examined lymph nodes are negative for cancer, which is a positive prognostic factor as it indicates no regional spread.

4. **Invasion**: There is no visceral pleural invasion or lymph-vascular invasion identified. The absence of these invasions is favorable as it suggests the tumor is less aggressive.

5. **Molecular Studies**: No EGFR mutations were detected. While the absence of EGFR mutations might limit certain targeted therapies, it does not necessarily worsen the prognosis significantly.

6. **Overall Assessment**: The combination of a relatively small tumor size, absence of lymph node involvement, and lack of invasive features suggests a more favorable prognosis. Although Stage IIB indicates a more advanced local disease, the absence of metastasis and invasive features supports a reasonable chance of survival beyond 2.48 years.

Based on these considerations, the patient is likely to survive beyond 2.48 years.

Answer - {""Survival"": ""True""}"
31,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Diagnosis and Tumor Characteristics**:
   - The patient has a diagnosis of non-small cell carcinoma, specifically poorly differentiated adenocarcinoma, in the right lower lobe of the lung.
   - The tumor size is 3.5 cm, which is relatively small.

2. **Invasion**:
   - There is evidence of invasion into the visceral pleura and large vessels. This indicates a more aggressive tumor behavior and potential for spread.

3. **Lymph Node Involvement**:
   - Metastases are present in the ipsilateral peribronchial and hilar lymph nodes. This suggests regional spread of the cancer, which is a negative prognostic factor.
   - Multiple lymph node biopsies from various stations were negative for malignancy, indicating no distant lymph node involvement.

4. **Margins**:
   - The bronchial margins are free of tumor, with a 5 mm distance from the invasive carcinoma to the closest margin. This is a positive finding, as it suggests complete resection of the tumor.

5. **Overall Staging and Prognosis**:
   - The presence of lymph node metastases and invasion into visceral pleura and large vessels suggests at least stage II or III disease, depending on the exact staging criteria used.
   - Poor differentiation of the tumor is generally associated with a worse prognosis.

Considering these factors, the presence of lymph node metastases and invasion into visceral pleura and large vessels are significant negative prognostic indicators. While the tumor has been resected with clear margins, the regional spread and aggressive nature of the tumor suggest a lower likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""False""}"
32,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The primary tumor is a poorly differentiated adenocarcinoma measuring 2.5 cm. Poor differentiation generally indicates a more aggressive tumor, but the small size (2.5 cm) is a favorable factor.

2. **Surgical Margins**: The surgical margins are uninvolved, which is a positive indicator as it suggests that the tumor was completely resected.

3. **Visceral Pleural Invasion**: There is a suggestion of visceral pleural invasion. Pleural invasion can be associated with a worse prognosis, but it is not definitive in this report.

4. **Residual Malignancy**: The right lower lobe lobectomy showed no residual malignancy, which is a positive finding indicating that the resection was likely successful in removing the tumor.

5. **Lymph Node Involvement**: Among the examined lymph nodes, only the level 12 nodes demonstrated evidence of metastasis. The presence of lymph node metastasis is a negative prognostic factor, but it is limited to one level, which may still allow for a favorable outcome if managed appropriately.

6. **Other Lymph Nodes**: The other lymph nodes showed no metastatic involvement, which is a positive factor.

Considering these factors, the presence of poorly differentiated adenocarcinoma and lymph node metastasis at level 12 are concerning. However, the small tumor size, uninvolved surgical margins, absence of residual malignancy, and limited lymph node involvement suggest a potentially favorable outcome with appropriate treatment.

Based on this analysis, the likelihood of survival after 2.48 years is cautiously optimistic, but the presence of metastasis does introduce some risk.

Answer - {""Survival"": ""True""}"
33,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The tumor is a poorly differentiated adenocarcinoma, which generally indicates a more aggressive cancer with a poorer prognosis compared to well-differentiated tumors.

2. **Size and Invasion**: The tumor measures 3.5 cm and invades the pleura. Pleural invasion can be associated with a worse prognosis, as it indicates more advanced local disease.

3. **Surgical Margins**: The surgical margins are negative for tumor, which is a positive factor, as it suggests that the tumor was completely resected.

4. **Vascular Invasion**: The presence of vascular invasion is a negative prognostic factor, as it suggests a higher likelihood of the cancer spreading through the bloodstream.

5. **Lymph Node and Metastasis**: There is no evidence of regional lymph node involvement or distant metastasis, which are positive factors, as the absence of these suggests that the cancer has not spread beyond the primary site.

Considering these factors, the presence of poorly differentiated histology and vascular invasion are significant negative prognostic indicators. However, the absence of lymph node involvement and distant metastasis, along with negative surgical margins, are positive indicators. The balance of these factors suggests a moderate risk of recurrence or progression, but not definitively poor enough to predict non-survival within 2.48 years.

Therefore, the likelihood of survival after 2.48 years is more favorable than not, given the absence of metastasis and complete resection, despite the negative factors.

Answer - {""Survival"": ""True""}"
34,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes a 2.8 cm invasive moderately differentiated adenocarcinoma. Moderate differentiation generally indicates an intermediate prognosis compared to well-differentiated (better prognosis) and poorly differentiated (worse prognosis) tumors.

2. **Invasion**: There is angiolymphatic and visceral pleural invasion. Angiolymphatic invasion can be a negative prognostic factor as it suggests potential for metastasis. Visceral pleural invasion also indicates a more aggressive tumor behavior.

3. **Lymph Nodes**: All sampled lymph nodes are benign, which is a positive finding as it suggests no regional lymph node metastasis.

4. **Surgical Margins**: The surgical resection margins are free of tumor, indicating that the tumor was likely completely resected, which is a favorable prognostic factor.

5. **Pathologic Stage**: The tumor is staged as T2N0MX. T2 indicates a tumor size greater than 3 cm but less than 5 cm or involvement of the main bronchus or visceral pleura. N0 indicates no regional lymph node involvement, which is favorable. MX indicates that distant metastasis cannot be assessed, but no evidence of metastasis is provided in the report.

6. **Additional Findings**: Chronic inflammation, submucosal scarring, and emphysematous changes are noted, but these are not directly related to the cancer prognosis.

Considering these factors, the absence of lymph node involvement and clear surgical margins are positive indicators for survival. However, the presence of angiolymphatic and visceral pleural invasion suggests a more aggressive tumor. Overall, the prognosis is mixed, but the absence of lymph node involvement and clear margins are significant positive factors.

Based on the information provided, the likelihood of survival after 2.48 years is more favorable than not, given the complete resection and lack of lymph node involvement.

Answer - {""Survival"": ""True""}"
35,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key details:

1. **Diagnosis**: The patient has a poorly differentiated non-small cell carcinoma, specifically adenocarcinoma, originating from the lung. Poor differentiation generally indicates a more aggressive tumor, which can be associated with a worse prognosis.

2. **Tumor Size and Unifocality**: The tumor measures 5.5 x 5.0 cm and is unifocal. While the size is relatively large, the fact that it is unifocal (a single tumor) is somewhat favorable compared to multifocal disease.

3. **Lymph Node Involvement**: All examined lymph nodes are negative for carcinoma. The absence of lymph node metastasis is a positive prognostic factor, as lymph node involvement often indicates a higher stage and worse prognosis.

4. **Immunohistochemical Staining**: The tumor is TTF-1 positive and negative for p63, CK5/6, CK7, and CK20, supporting the diagnosis of adenocarcinoma. This immunoprofile helps confirm the primary lung origin of the tumor.

5. **Pending Further Characterization**: Additional immunoevaluation is pending, which may provide more insights into the tumor's behavior and potential treatment options.

Considering these factors, the absence of lymph node involvement is a significant positive factor, despite the poor differentiation of the tumor. While poor differentiation can indicate a more aggressive cancer, the lack of lymph node metastasis suggests that the disease may be more localized, which can improve the prognosis.

Based on the information provided, the likelihood of survival after 2.48 years is more favorable due to the absence of lymph node involvement, despite the poor differentiation of the tumor.

Answer - {""Survival"": ""True""}"
36,"To determine if the patient will survive after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes a poorly differentiated adenocarcinoma with clear cell changes, measuring 7 cm. Poor differentiation generally indicates a more aggressive tumor, but other factors must be considered.

2. **Visceral Pleura Invasion**: There is no invasion of the visceral pleura, which is a positive prognostic factor as pleural invasion can indicate a more advanced disease.

3. **Margins**: The bronchial and vascular margins are negative, meaning the tumor was completely resected with no cancer cells at the edges of the removed tissue. This is a favorable finding as it suggests that the cancer has been fully removed.

4. **Lymph Nodes**: All examined lymph nodes from levels 4, 7, and 9 show no evidence of tumor. The absence of lymph node involvement is a strong positive prognostic factor, as lymph node metastasis is associated with a higher risk of recurrence and poorer outcomes.

5. **Sixth Rib**: The portion of the sixth rib examined also shows no evidence of tumor, indicating no local spread to the bone.

6. **Overall Findings**: The report suggests a successful resection of the lung cancer with clear margins and no metastatic spread to the sampled lymph nodes. These findings are generally associated with a better prognosis and a higher likelihood of survival beyond 2.48 years.

Considering these factors, the prognosis appears favorable due to the complete resection, lack of pleural invasion, and absence of lymph node metastasis. Therefore, the likelihood of survival after 2.48 years is high.

Answer - {""Survival"": ""True""}"
37,"The pathology report provides the following key information:

1. **Tumor Type and Size**: The tumor is a mixed acinar and bronchioloalveolar adenocarcinoma measuring 3.5 cm, with moderate to poorly differentiated histology. Poor differentiation generally indicates a more aggressive tumor.

2. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in one of two resected lymph nodes. Lymph node involvement is a significant factor in cancer staging and prognosis, often indicating a higher stage and a worse prognosis.

3. **KRAS Mutation**: The presence of a KRAS mutation, particularly in codon 12 or 13, is associated with a poorer prognosis and potential resistance to certain therapies. KRAS mutations are known to be negative prognostic markers in lung adenocarcinoma.

4. **Other Lymph Nodes and Tissue**: The remaining lymph nodes and associated fibroadipose tissue were negative for tumor, which is a positive finding, but the presence of metastasis in one lymph node is concerning.

Considering these factors, the presence of metastatic disease in a lymph node and the KRAS mutation suggest a more aggressive cancer with a poorer prognosis. While the tumor size is relatively small, the lymph node involvement and genetic mutation are significant negative prognostic indicators.

Based on this analysis, the likelihood of survival after 2.48 years is reduced, leading to the conclusion:

Answer - {""Survival"": ""False""}"
